Pathology of Gastric Cancer and Its Precursor Lesions

Gastroenterology Clinics of North America

Volumn 42, Issue 2, 2013, Pages 261-284

  Yakirevich, Evgeny ^a   Resnick, Murray B ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Atrophic gastritis; Chronic gastritis; Diffuse (signet ring) type adenocarcinoma; Helicobacter pylori; Intestinal metaplasia; Intestinal type adenocarcinoma; Proximal gastric cancer; Spasmolytic polypeptide expressing metaplasia

Indexed keywords

POLYPEPTIDE; SPASMOLYTIC POLYPEPTIDE; UNCLASSIFIED DRUG; UVOMORULIN;

ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CARNEIRO MODEL; CDH1 GENE; CHRONIC GASTRITIS; CLINICAL FEATURE; CORREA MODEL; DISEASE ASSOCIATION; DYSPLASIA; GASTROESOPHAGEAL REFLUX; GENE; GENOMIC INSTABILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; METAPLASIA; MODEL; ONCOGENE; POLYPOSIS SYNDROME; PRECANCER; PROTEIN EXPRESSION; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH POLYP; SYNDROME; TP53 GENE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMA; AUTOIMMUNE DISEASES; CARCINOGENESIS; CARDIA; CHRONIC DISEASE; GASTRITIS; GASTRITIS, ATROPHIC; GENES, TUMOR SUPPRESSOR; GENOMIC INSTABILITY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA; ONCOGENES; STOMACH; STOMACH NEOPLASMS;

EID: 84877037180     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2013.01.004     Document Type: Review

References (136)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988, 48:3554-3560.
3. Borrmann R. Geshwulste des Magens und Duodenums. Handbuch der Speziellen Pathologischen Anatomie und Histologie 1926, 865. Springer-Verlag, Berlin. F. Henke, O. Lubrasch (Eds.).
4. Ming S.C. Gastric carcinoma. A pathobiological classification. Cancer 1977, 39:2475-2485.
5. Carneiro F. Classification of gastric carcinomas. Curr Diagn Pathol 1997, 4:51-59.
6. Goseki N., Takizawa T., Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut 1992, 33:606-612.
7. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
8. Lauwers G.Y., Carneiro F., Graham D.Y., et al. Gastric carcinoma. WHO classification of tumours of the digestive system 2010, 48-58. IARC Press, Lyon (France). 4th edition. F.T. Bosman, F. Carneiro, R.H. Hruban (Eds.).
9. Tay S.T., Leong S.H., Yu K., et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res 2003, 63:3309-3316.
10. Tan I.B., Ivanova T., Lim K.H., et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011, 141:476-485.
11. Lee H.S., Cho S.B., Lee H.E., et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 2007, 13:4154-4163.
12. Henson D.E., Dittus C., Younes M., et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med 2004, 128:765-770.
13. Fuchs C.S., Mayer R.J. Gastric carcinoma. N Engl J Med 1995, 333:32-41.
14. Eom D.W., Kang G.H., Han S.H., et al. Gastric micropapillary carcinoma: a distinct subtype with a significantly worse prognosis in TNM stages I and II. Am J Surg Pathol 2011, 35:84-91.
15. Carneiro F., Huntsman D.G., Smyrk T.C., et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004, 203:681-687.
16. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res 1992, 52:6735-6740.
17. Dixon M.F., Genta R.M., Yardley J.H., et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20:1161-1181.
18. Rugge M., Genta R.M., OLGA Group Staging gastritis: an international proposal. Gastroenterology 2005, 129:1807-1808.
19. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994, 61:1-241.
20. Fox J.G., Wang T.C. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007, 117:60-69.
21. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784-789.
22. Helicobacter and Cancer Collaborative Group Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001, 49:347-353.
23. Huang J.Q., Sridhar S., Chen Y., et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998, 114:1169-1179.
24. Smith S.B., Snow A.N., Perry R.L., et al. Helicobacter pylori: to stain or not to stain?. Am J Clin Pathol 2012, 137:733-738.
25. Hartman D.J., Owens S.R. Are routine ancillary stains required to diagnose Helicobacter infection in gastric biopsy specimens? An institutional quality assurance review. Am J Clin Pathol 2012, 137:255-260.
26. Strickland R.G. The Sydney System: auto-immune gastritis. J Gastroenterol Hepatol 1991, 6:238-243.
27. Brinton L.A., Gridley G., Hrubec Z., et al. Cancer risk following pernicious anaemia. Br J Cancer 1989, 59:810-813.
28. Hsing A.W., Hansson L.E., McLaughlin J.K., et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993, 71:745-750.
29. Solcia E., Rindi G., Fiocca R., et al. Distinct patterns of chronic gastritis associated with carcinoid and cancer and their role in tumorigenesis. Yale J Biol Med 1992, 65:793-804.
30. Rugge M., Meggio A., Pennelli G., et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007, 56:631-636.
31. Rugge M., de Boni M., Pennelli G., et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010, 31:1104-1111.
32. Robbins and Cotran Pathologic basis of disease 2010, 10. Saunders/Elsevier, Philadelphia. 8th edition. V. Kumar (Ed.).
33. Schmidt P.H., Lee J.R., Joshi V., et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 1999, 79:639-646.
34. Goldenring J.R., Nam K.T., Wang T.C., et al. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010, 138:2207-2210.
35. Wong W.M., Poulsom R., Wright N.A. Trefoil peptides. Gut 1999, 44:890-895.
36. Halldórsdóttir A.M., Sigurdardóttrir M., Jónasson J.G., et al. Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci 2003, 48:431-441.
37. Yamaguchi H., Goldenring J.R., Kaminishi M., et al. Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci 2002, 47:573-578.
38. Goldenring J.R., Nam K.T. Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci 2010, 96:117-131.
39. El-Zimaity H.M., Ota H., Graham D.Y., et al. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 2002, 94:1428-1436.
40. Jass J.R., Filipe M.I. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981, 13:931-939.
41. Reis C.A., David L., Correa P., et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999, 59:1003-1007.
42. Filipe M.I., Potet F., Bogomoletz W.V., et al. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut 1985, 26:1319-1326.
43. Jass J.R., Filipe M.I. Sulphomucins and precancerous lesions of the human stomach. Histopathology 1980, 4:271-279.
44. Barros R., Freund J.N., David L., et al. Gastric intestinal metaplasia revisited: function and regulation of CDX2. Trends Mol Med 2012, 18:555-563.
45. Pagnini C.A., Bozzola L. Precancerous significance of colonic type intestinal metaplasia. Tumori 1981, 67:113-116.
46. Filipe M.I., Muñoz N., Matko I., et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994, 57:324-329.
47. Capelle L.G., de Vries A.C., Haringsma J., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010, 71:1150-1158.
48. Correa P., Fontham E.T., Bravo J.C., et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000, 92:1881-1888.
49. Ley C., Mohar A., Guarner J., et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004, 13:4-10.
50. Zhou L., Sung J.J., Lin S., et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) 2003, 116:11-14.
51. Wong B.C., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004, 291:187-194. China Gastric Cancer Study Group.
52. Asfeldt A.M., Steigen S.E., Løchen M.L., et al. The natural course of Helicobacter pylori infection on endoscopic findings in a population during 17 years of follow-up: the Sørreisa gastrointestinal disorder study. Eur J Epidemiol 2009, 24:649-658.
53. Barros R., Peleteiro B., Almeida R., et al. Relevance of high virulence Helicobacter pylori strains and futility of CDX2 expression for predicting intestinal metaplasia after eradication of infection. Scand J Gastroenterol 2010, 45:828-834.
54. Odze R.D., Riddell R.H., Bosman F.T., et al. Premalignant lesions of the digestive system. WHO Classification of tumours of the digestive system 2010, 10-12. IARC Press, Lyon (France). 4th edition. F.T. Bosman (Ed.).
55. Rugge M., Correa P., Dixon M.F., et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000, 24:167-176.
56. Schlemper R.J., Riddell R.H., Kato Y., et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000, 47:251-255.
57. Lauwers G.Y., Shimizu M., Correa P., et al. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. Am J Surg Pathol 1999, 23:511-518.
58. Shin N., Jo H.J., Kim W.K., et al. Gastric pit dysplasia in adjacent gastric mucosa in 414 gastric cancers: prevalence and characteristics. Am J Surg Pathol 2011, 35:1021-1029.
59. Jass J.R. A classification of gastric dysplasia. Histopathology 1983, 7(2):181-193.
60. Lauwers G.Y., Riddell R.H. Gastric epithelial dysplasia. Gut 1999, 45:784-790.
61. Park do Y., Srivastava A., Kim G.H., et al. Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. Am J Surg Pathol 2008, 32:524-533.
62. Park do Y., Srivastava A., Kim G.H., et al. CDX2 expression in the intestinal-type gastri epithelial neoplasia: frequency and significance. Mod Pathol 2010, 23:54-61.
63. Nogueira A.M., Machado J.C., Carneiro F., et al. Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. J Pathol 1999, 187:541-548.
64. Abraham S.C., Montgomery E.A., Singh V.K., et al. Gastric adenomas: intestinal-type and gastric-type adenomas differ in the risk of adenocarcinoma and presence of background mucosal pathology. Am J Surg Pathol 2002, 26:1276-1285.
65. Srivastava A., Lauwers G.Y. Gastric epithelial dysplasia: the Western perspective. Dig Liver Dis 2008, 40(8):641-649.
66. Yamada H., Ikegami M., Shimoda T., et al. Long term follow-up study of gastric adenoma/dysplasia. Endoscopy 2004, 36:390-396.
67. Dinis-Ribeiro M., Areia M., de Vries A.C., European Society of Gastrointestinal Endoscopy, European Helicobacter Study Group, European Society of Pathology, Sociedade Portuguesa de Endoscopia Digestiva, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012, 44:74-94.
68. Kim Y.J., Park J.C., Kim J.H., et al. Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions. Endoscopy 2010, 42:620-626.
69. Won C.S., Cho M.Y., Kim H.S., et al. Upgrade of lesions initially diagnosed as low-grade gastric dysplasia upon forceps biopsy following endoscopic resection. Gut Liver 2011, 5:187-193.
70. Kasuga A., Yamamoto Y., Fujisaki J., et al. Clinical characterization of gastric lesions initially diagnosed as low-grade adenomas on forceps biopsy. Dig Endosc 2012, 24:331-338.
71. de Vries A.C., van Grieken N.C., Looman C.W., et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008, 134:945-952.
72. Park do Y., Lauwers G.Y. Gastric polyps: classification and management. Arch Pathol Lab Med 2008, 132:633-640.
73. Carmack S.W., Genta R.M., Schuler C.M., et al. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009, 104:1524-1532.
74. Genta R.M., Schuler C.M., Robiou C.I., et al. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin Gastroenterol Hepatol 2009, 7:849-854.
75. Zwick A., Munir M., Ryan C.K., et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997, 113:659-663.
76. Worthley D.L., Phillips K.D., Wayte N., et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012, 61:774-779.
77. Carmack S.W., Genta R.M., Graham D.Y., et al. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol 2009, 6:331-341.
78. Rubio C.A. Paneth cell adenoma of the stomach. Am J Surg Pathol 1989, 13:325-328.
79. Vieth M., Kushima R., Borchard F., et al. Pyloric gland adenoma: a clinico-pathological analysis of 90 cases. Virchows Arch 2003, 442:317-321.
80. Chen Z.M., Scudiere J.R., Abraham S.C., et al. Pyloric gland adenoma: an entity distinct from gastric foveolar type adenoma. Am J Surg Pathol 2009, 33:186-193.
81. Singhi A.D., Lazenby A.J., Montgomery E.A. Gastric adenocarcinoma with chief cell differentiation: a proposal for reclassification as oxyntic gland polyp/adenoma. Am J Surg Pathol 2012, 36:1030-1035.
82. Everett S.M., Axon A.T. Early gastric cancer in Europe. Gut 1997, 41:142-150.
83. Alfaro E.E., Lauwers G.Y. Early gastric neoplasia: diagnosis and implications. Adv Anat Pathol 2011, 18:268-280.
84. Noguchi Y., Yoshikawa T., Tsuburaya A., et al. Is gastric carcinoma different between Japan and the United States?. Cancer 2000, 89:2237-2246.
85. Japanese Gastric Cancer Association Japanese classification of gastric carcinoma: 2nd English edition. Gastric Cancer 1998, 1:10-24.
86. Krasinskas A.M., Goldsmith J.D. Immunohistology of the gastrointestinal tract. Diagnostic immunohistochemistry 2010, 505-511. WB Saunders, Philadelphia. 3rd edition. D.J. Dabbs (Ed.).
87. Gürbüz Y., Kahlke V., Klöppel G. How do gastric carcinoma classification systems relate to mucin expression patterns? An immunohistochemical analysis in a series of advanced gastric carcinomas. Virchows Arch 2002, 440:505-511.
88. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004, 157:327-349.
89. Brito M.J., Williams G.T., Thompson H., et al. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut 1994, 35:1697-1700.
90. Lauwers G.Y., Wahl S.J., Melamed J., et al. p53 expression in precancerous gastric lesions: an immunohistochemical study of PAb 1801 monoclonal antibody on adenomatous and hyperplastic gastric polyps. Am J Gastroenterol 1993, 88:1916-1919.
91. Joypaul B.V., Newman E.L., Hopwood D., et al. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. J Pathol 1993, 170:279-283.
92. Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805.
93. Bang Y.J., Van Cutsem E., Feyereislova A., et al. ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
94. Kim M.A., Lee H.S., Lee H.E., et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008, 52:738-746.
95. Pinto C., Di Fabio F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007, 18:510-517.
96. Han S.W., Oh D.Y., Im S.A., et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009, 100:298-304.
97. Yoon H.H., Shi Q., Sukov W.R., et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012, 18:546-554.
98. Rüschoff J., Hanna W., Bilous M., et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012, 25:637-650.
99. Fassan M., Mastracci L., Grillo F., et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 2012, 61:769-776.
100. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214-218.
101. Kang G.H., Lee S., Kim J.S., et al. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003, 83:635-641.
102. Kang G.H., Lee S., Cho N.Y., et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 2008, 88:161-170.
103. Park S.Y., Kook M.C., Kim Y.W., et al. CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. Virchows Arch 2010, 457:415-422.
104. Chiaravalli A.M., Klersy C., Tava F., et al. Lower- and higher-grade subtypes of diffuse gastric cancer. Hum Pathol 2009, 40:1591-1599.
105. Carneiro F. Hereditary gastric cancer. Pathologe 2012, 33(Suppl 2):231-234.
106. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
107. Resnick M.B., Gavilanez M., Newton E., et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 2005, 36:886-892.
108. Jee H., Nam K.T., Kwon H.J., et al. Altered expression and localization of connexin32 in human and murine gastric carcinogenesis. Dig Dis Sci 2011, 56:1323-1332.
109. Fitzgerald R.C., Hardwick R., Huntsman D., International Gastric Cancer Linkage Consortium, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436-444.
110. Corso G., Pedrazzani C., Pinheiro H., et al. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer 2011, 47:631-639.
111. Carneiro P., Fernandes M.S., Figueiredo J., et al. E-cadherin dysfunction in gastric cancer-cellular consequences, clinical applications and open questions. FEBS Lett 2012, 586:2981-2989.
112. Becker K.F., Atkinson M.J., Reich U., et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994, 54:3845-3852.
113. Schuetz J.M., Leach S., Kaurah P., et al. Catenin family genes are not commonly mutated in hereditary diffuse gastric cancer. Cancer Epidemiol Biomarkers Prev 2012, 21(12):2272-2274.
114. Charlton A., Blair V., Shaw D., et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 2004, 53:814-820.
115. Guilford P., Humar B., Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 2010, 13:1-10.
116. Solcia E., Fiocca R., Cornaggia M., et al. Precancerous lesions of the stomach. Problems and controversies in gastroenterology 1985, 241-248. Raven Press, New York. G. Dobrilla, G. Bertaccini, M.J. Langman (Eds.).
117. Chan A.O., Lam S.K., Wong B.C., et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003, 52:502-506.
118. Chan A.O., Huang C., Hui W.M., et al. Stability of E-cadherin methylation status in gastric mucosa associated with histology changes. Aliment Pharmacol Ther 2006, 24:831-836.
119. Kubo T. Histologic appearance of gastric carcinoma in high and low mortality countries: comparison between Kyushu, Japan and Minnesota, USA. Cancer 1971, 28:726-734.
120. Hyung W.J., Noh S.H., Lee J.H., et al. Early gastric carcinoma with signet ring cell histology. Cancer 2002, 94:78-83.
121. Chiu C.T., Kuo C.J., Yeh T.S., et al. Early signet ring cell gastric cancer. Dig Dis Sci 2011, 56:1749-1756.
122. Li C., Kim S., Lai J.F., et al. Advanced gastric carcinoma with signet ring cell histology. Oncology 2007, 72:64-68.
123. Devesa S.S., Blot W.J., Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
124. Glickman J.N., Fox V., Antonioli D.A., et al. Morphology of the cardia and significance of carditis in pediatric patients. Am J Surg Pathol 2002, 26:1032-1039.
125. Chandrasoma P.T., Der R., Ma Y., et al. Histology of the gastroesophageal junction: an autopsy study. Am J Surg Pathol 2000, 24:402-409.
126. International classification of diseases. 9th revision, clinical modification (ICD-9-CM) 2008, National Center for Health Statistics, Hyattsville (MD). 6th edition.
127. AJCC cancer staging manual 2010, 103-115. Springer-Verlag, New York. 7th edition. S.B. Edge (Ed.).
128. Carneiro F., Chaves P. Pathologic risk factors of adenocarcinoma of the gastric cardia and gastroesophageal junction. Surg Oncol Clin N Am 2006, 15:697-714.
129. Derakhshan M.H., Malekzadeh R., Watabe H., et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008, 57(3):298-305.
130. Wijetunge S., Ma Y., DeMeester S., et al. Association of adenocarcinomas of the distal esophagus, " gastroesophageal junction," and " gastric cardia" with gastric pathology. Am J Surg Pathol 2010, 34:1521-1527.
131. Demicco E.G., Farris A.B., Baba Y., et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 2011, 24:1177-1190.
132. Khor T.S., Alfaro E.E., Ooi E.M., et al. Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus?. Am J Surg Pathol 2012, 36:331-342.
133. Oh D.S., DeMeester S.R., Tanaka K., et al. The gene expression profile of cardia intestinal metaplasia is similar to that of Barrett's esophagus, not gastric intestinal metaplasia. Dis Esophagus 2011, 24:516-522.
134. Dawsey S.M., Mark S.D., Taylor P.R., et al. Gastric cancer and H. pylori. Gut 2002, 51:457-458.
135. Cavaleiro-Pinto M., Peleteiro B., Lunet N., et al. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control 2011, 22(3):375-387.
136. Kamangar F., Dawsey S.M., Blaser M.J., et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006, 98:1445-1452.